HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Banarer, S. Search for Related Content PubMed PubMed Citation Articles by Banarer, S. Social Bookmarking                What's this?

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study

Response to Porcellati et al.

From the Dallas Diabetes and Endocrine Center, Dallas, Texas

Address correspondence to Salomon Banarer, Dallas Diabetes and Endocrine Center, 7777 Forest Ln. C-685, Dallas, TX 75230. E-mail: salomonbanarer@dallasdiabetes.com

The first 20% of the full text of this article appears below.

I congratulate Porcellati et al. (1) for a long-awaited comparison of glargine and detemir pharmacodynamics. They clearly show that the duration of action for glargine (but not detemir) is greater than 24 h.

One of the major differences can be seen in the glucose infusion rate (GIR). At 12 h postinjection, glargine has higher area under the curve (AUC) GIR remaining (42 vs. 15%). The presence of GIR, a marker of insulin-mediated glucose disposal, proves the longer pharmacodynamic effect of glargine.

Even so, the report of the insulin activity profile is confusing. The authors . . . [Full Text of this Article]

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Porcellati, P. Rossetti, G. B. Bolli, and C. G. Fanelli Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study: Response to Banarer Diabetes Care, March 1, 2008; 31(3): e17 - e17. [Full Text] [PDF]